Lucid Diagnostics’ EsoGuard cancer diagnosis test highlighted in publication

Lucid Diagnostics (LUCD) announced the peer-reviewed publication of an analytical validation study of its EsoGuard Esophageal DNA test for the diagnosis of esophageal precancer and esophageal adenocarcinoma on samples collected non-endoscopically using Lucid’s EsoCheck Esophageal Cell Collection Device. The manuscript has been published in the peer-reviewed journal Diagnostics. The publication details studies demonstrating “excellent analytical performance” of the EsoGuard assay on samples collected with EsoCheck, including 89% analytical sensitivity, 100% analytical specificity, 96% analytical accuracy, and 100% inter- and intra-assay precision. Lucid Diagnostics is a subsidiary of PAVmed (PAVM).